Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 3 OTHER 1 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 3 Carcinoma, Non-Small-Cell Lung 2 Stomach Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Adenocarcinoma 1

Interventions

Docetaxel 171 Radiotherapy 144 Magnetic Resonance Spectroscopy 142 Leuprolide 112 Prednisone 108 enzalutamide 102 Radiosurgery 101 Abiraterone Acetate 94 Androgen Antagonists 91 Goserelin 83 bicalutamide 81 gallium 68 PSMA-11 70 Surveys and Questionnaires 63 apalutamide 57 Specimen Handling 56 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55 Radiation 47 Gonadotropin-Releasing Hormone 45 Standard of Care 44 Biopsy 44 Brachytherapy 42 Radiotherapy, Intensity-Modulated 40 Blood Specimen Collection 40 darolutamide 39 abiraterone 39 cabazitaxel 35 Exercise 35 Carboplatin 33 Pluvicto 32 Triptorelin Pamoate 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Prostatic Neoplasms × ipatasertib × Clear all

NCT04737109 2023-11-13

ADDItion

Big Ten Cancer Research Consortium

Phase 1/2 Terminated

6 enrolled 9 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡